Navigation Links
Breast cancer drug shows promise for treating, preventing progestin-dependent tumors
Date:1/28/2009

COLUMBIA, Mo. Recent studies suggest that human breast cancer risk is increased by outside exposure to the hormone progestin, such as during hormone replacement therapy. Now, a University of Missouri study suggests that PRIMA-1, a small molecule drug that targets the most common mutated gene, p53, in human cancer cells, has potential as a novel chemotherapeutic treatment for progestin-accelerated human breast cancer.

"We demonstrated that PRIMA-1 was an effective drug to treat and prevent emergence of progestin-accelerated mammary tumors in rats," said Salman Hyder, professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "The results of this study may have significant implications for the treatment and prevention of human breast cancer because such a large fraction of human breast cancers are dependent on estrogens and progestins for growth."

Mutated p53 plays a key role in promoting tumor cell survival and tumor cell resistance to chemotherapeutic drugs. In more than 50 percent of breast cancer cases, mutated p53 is present. Previous research has indicated that when p53 is functionally abnormal, tumor cells are prolific and develop quickly. PRIMA-1 targets and returns normal function to the mutated p53.

In the study, researchers examined the ability of PRIMA-1 to suppress growth of progestin-accelerated, mammary tumors in an animal model. When tumors reached a certain size, researchers administrated PRIMA-1 twice a day for three days. The researchers found that PRIMA-1 caused regression of approximately 40 percent of progestin-accelerated mammary tumors. However, the drug did not induce regression of native, non-progestin accelerated tumors. PRIMA-1 also suppressed the emergence of any new progestin-accelerated tumors in the animal model.

"Postmenopausal women worldwide are exposed to exogenous progestin in the form of hormone replacement therapy, and clinical studies have associated combined exposure to progestin and estrogen with an increased incidence of human breast cancer in this population," said Hyder, who is also the Zalk Endowed Professor of Tumor Angiogenesis. "Because PRIMA-1 blocked the formation of new tumors following progestin stimulation in this experimental model, it is tempting to speculate that this agent could be used to prevent progestin-accelerated tumors in women on hormone replacement therapy. However, this needs to be tested thoroughly in a clinical setting."


'/>"/>

Contact: Kelsey Jackson
JacksonKN@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... For many women, getting birth control isn’t as easy as it should ... don’t have access to a health care facility or a pharmacy within 60 minutes of ... United States or for many who are faced with health or personal issues that leave ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors ... brings his extensive knowledge of appraisals, property values, ad valorem taxation, and government ... valuation industry for more than 40 years. , “Ruel is a great addition ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution ... legislatures and Congress to protect parental rights and civil liberties, and to restore ... America. , The demonstration coincides with a press conference taking place Friday morning ...
(Date:3/28/2017)... ... 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading ... The Thyroid Secret. Dr. Wentz talked about journey and research recently on a blog ... IS NOT the only solution to deal with thyroid disease. , Dr. Wentz ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... management software and services, is proud to announce it has joined the National ... association representing the interests of chronically ill, disabled, and dying Americans of all ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017 Varian Medical Systems (NYSE: ... the second quarter of fiscal year 2017 following the close ... release will be followed by a teleconference available to all ... a link to the conference call webcast will be available ... the teleconference call and replay: ...
(Date:3/29/2017)... 2017  NuVasive, Inc. (NASDAQ: NUVA), a leading ... with minimally disruptive, procedurally-integrated solutions, today announced U.S. ... the CoRoent® Small Interbody™ System indicated for intervertebral ... cervical spine. This marks the first U.S. clearance ... up to four contiguous levels. Cervical ...
(Date:3/29/2017)... NetworkNewsWire Editorial Coverage  ... There are a number ... marijuana, but economic arguments also favor its legalization. The benefits ... costs. However, to legalize and regulate marijuana requires an ecosystem ... SING) ( SING Profile ), American Cannabis Company (OTC: AMMJ), ...
Breaking Medicine Technology: